VRCA NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Verrica Pharmaceuticals Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 5.02 USD
-10.2% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -19.3% below the Trend Line and sits at 26.6% of its 52-week range. The latest completed week returned -10.2%, after a -26.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 55/100. Near-term considerations: volume confirmation is below normal; earnings are due in 13d.

Setup score 10 out of 100
Latest Close 5.02 USD 24 Jul 2026
1W Return -10.2% latest completed week
4W Return -26.6% short-term follow-through
12W Return -19.9% quarterly tape
Trend Breadth 19.2% 10 of 52 weeks active
Volume Ratio 0.3x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -10.2% Latest completed week; four-week move -26.6%. Indicator stack 11/0 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 44.24% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 55/100 72 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -19.3% below the Trend Line and sits at 26.6% of its 52-week range. The latest completed week returned -10.2%, after a -26.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.3x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1412-week average 0.17

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure9/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership1/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.14Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -26.6% over four weeks, -19.9% over 12 weeks, and -24.1% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-10.2%
4W-26.6%
12W-19.9%
26W-32.3%
52W-24.1%
Active trend streak0 weeks
Active weeks in one year10
Trend breadth19.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.40Latest activity-pressure read.
Pressure change-1252.0%Four-week change in activity pressure.
Leadership-22.16Latest relative-leadership reading.
RS change-1366.5%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 79% Model confidence 76%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength16/100Blend of value, momentum, and quality. Underlying universe rank 85; rank 1 is best.
Value22/100Relative valuation strength. Underlying universe rank 79; rank 1 is best.
Quality69/100Profitability and accounting quality. Underlying universe rank 32; rank 1 is best.
Momentum19/100Medium-term price momentum. Underlying universe rank 82; rank 1 is best.
Growth91/100Revenue and earnings growth. Underlying universe rank 10; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
2.3x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-21.0%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
89.5%
Gross profit retained from each unit of revenue.
Operating margin
-32.6%
Operating profit retained from revenue.
Free-cash-flow margin
-38.0%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
417.6%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-58.1%
Net share repurchases relative to market value.
Shareholder yield
-58.1%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.7x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity7 / 0

7 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment55/100

Weighted news tone is neutral across 72 relevant articles.

19 positive · 46 neutral · 7 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-48.9%Distance below the 52-week high.
13-week volatility12.9%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher9 of 2617 weeks finished lower.
Best week+27.4%Week of 8 May.
Worst week-21.5%Week of 15 May.
Latest week-10.2%Week of 24 Jul.

Shape of recent returns

Strong gains7
Modest gains2
Flat weeks0
Modest losses4
Sharp losses13
Recent vol12.9%13-week weekly-return volatility.
Base vol19.4%52-week weekly-return volatility.
Up/down split19/33Count of positive and negative weeks in the 52-week window.
Average skew16.0% / -7.9%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape12/100

Trend, activity pressure, participation, and risk combine to a 12/100 tape read.

 Indicator analysis28/100

Latest 12-week confirmation: trend 0/12, activity pressure 9/12, relative leadership 1/12.

Activity pressure 0.14; No reversal markers Next-Week ExpectancyNegative 44.24%

Next-week expectancy is negative with a 44.24% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors31/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 97; Small Cap Core rank 81 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment55/100

Weighted news tone is neutral across 72 relevant articles.

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel Insiders7 / 0

7 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20265.02 USD-10.2%6.22 USD24.91 USD-0.40-22.1689.3KOff
17 Jul 20265.59 USD-10.7%6.32 USD25.25 USD0.03-15.46128.0KOff
10 Jul 20266.26 USD2.0%6.40 USD25.69 USD0.07-10.45175.6KOff
3 Jul 20266.13 USD-10.3%6.45 USD26.08 USD0.05-11.70159.6KOff
26 Jun 20266.84 USD21.5%6.54 USD26.44 USD0.03-1.51339.9KOff
19 Jun 20265.63 USD-1.7%6.62 USD26.76 USD-0.09-22.56113.5KOff
12 Jun 20265.73 USD-5.1%6.57 USD27.11 USD-0.01-19.64210.8KOff
5 Jun 20266.04 USD4.9%6.51 USD27.46 USD0.09-13.99181.1KOff
29 May 20265.76 USD-5.0%6.42 USD27.80 USD0.31-22.13132.4KOff
22 May 20266.06 USD-3.3%6.35 USD28.13 USD0.28-15.98238.3KOff
15 May 20266.27 USD-21.5%6.28 USD28.46 USD0.26-12.62492.0KOff
8 May 20267.99 USD27.4%6.21 USD28.80 USD0.1410.17787.6KOff
1 May 20266.27 USD-10.2%6.08 USD29.14 USD-0.29-8.41303.9KOff
24 Apr 20266.98 USD10.4%6.03 USD29.52 USD-0.453.47364.1KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.